Soliton, Inc. announced the appointment of Mary Stoll as Senior Director of Clinical Development. Ms. Stoll will have responsibility for direct oversight of all clinical activities of the Company's Rapid Acoustic Pulse device for tattoo removal, improvement in the appearance of cellulite, keloid (scarring), and additional pipeline indications. Mary Stoll joins Soliton from Cytrellis Biosystems where she served as Senior Director of Clinical Operations. At Cytrellis, she oversaw and lead all clinical operations activities for new technology targeting skin laxity and was responsible for promoting, executing, and establishing clinical strategies in line with the Company's mission and vision. Prior to her tenure with Cytrellis, she was the Executive Director of Clinical Services at Cynosure, a laser Company acquired by Hologic, Inc. Ms. Stoll holds a Bachelor in Science Health and Science Studies and a nursing degree both from Quinnipiac University.